These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 3205885)

  • 1. Adherence to lithium prophylaxis: II. Multivariate analysis of clinical, social, and psychosocial predictors of nonadherence.
    Aagaard J; Vestergaard P; Maarbjerg K
    Pharmacopsychiatry; 1988 Jul; 21(4):166-70. PubMed ID: 3205885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to lithium prophylaxis: I. Clinical predictors and patient's reasons for nonadherence.
    Maarbjerg K; Aagaard J; Vestergaard P
    Pharmacopsychiatry; 1988 May; 21(3):121-5. PubMed ID: 3406049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbamazepine as adjunct or alternative to lithium in the prophylaxis of recurrent affective disorders.
    Fritze J; Beneke M; Lanczik M; Schneider B; Walden J
    Pharmacopsychiatry; 1994 Sep; 27(5):181-5. PubMed ID: 7838887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylaxis of schizoaffective disorder with lithium or carbamazepine: outcome after long-term follow-up.
    Baethge C; Gruschka P; Berghöfer A; Bauer M; Müller-Oerlinghausen B; Bschor T; Smolka MN
    J Affect Disord; 2004 Apr; 79(1-3):43-50. PubMed ID: 15023479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Who responds to prophylactic lithium therapy?
    Abou-Saleh MT
    Br J Psychiatry Suppl; 1993 Sep; (21):20-6. PubMed ID: 8217063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Predictors of prophylactic response to lithium].
    Rohayem J; Baylé JF; Richa S
    Encephale; 2008 Sep; 34(4):394-9. PubMed ID: 18922242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between prophylactic effect of lithium therapy and family history of affective disorders.
    Engström C; Aström M; Nordqvist-Karlsson B; Adolfsson R; Nylander PO
    Biol Psychiatry; 1997 Sep; 42(6):425-33. PubMed ID: 9285078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical predictors of long-term outcome of lithium prophylaxis in bipolar disorder].
    Garcia-López A; Ezquiaga E; Nieves P; Rodríguez-Salvanés F
    Actas Esp Psiquiatr; 2001; 29(5):327-32. PubMed ID: 11602090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effectiveness of lithium in the prophylaxis of affective disorders].
    Ezquiaga E; García-López A; Nieves P; Rodríguez-Salvanés F
    Actas Esp Psiquiatr; 2000; 28(3):156-60. PubMed ID: 11000697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality in 497 patients with affective disorders attending a lithium clinic or after having left it.
    Kallner G; Lindelius R; Petterson U; Stockman O; Tham A
    Pharmacopsychiatry; 2000 Jan; 33(1):8-13. PubMed ID: 10721878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The challenge of predicting response to stabilising lithium treatment. The importance of patient selection.
    Grof P; Alda M; Grof E; Fox D; Cameron P
    Br J Psychiatry Suppl; 1993 Sep; (21):16-9. PubMed ID: 8217062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classifying mood disorders by age-at-onset instead of polarity.
    Benazzi F
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Feb; 33(1):86-93. PubMed ID: 18992784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loudness dependence of primary auditory-cortex-evoked activity as predictor of therapeutic outcome to prophylactic lithium treatment in affective disorders--a retrospective study.
    Juckel G; Mavrogiorgou P; Bredemeier S; Gallinat J; Frodl T; Schulz C; Möller HJ; Hegerl U
    Pharmacopsychiatry; 2004 Mar; 37(2):46-51. PubMed ID: 15048610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compliance with long-term lithium treatment in major affective disorders.
    Danion JM; Neunreuther C; Krieger-Finance F; Imbs JL; Singer L
    Pharmacopsychiatry; 1987 Sep; 20(5):230-1. PubMed ID: 3671494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of compliance with lithium and carbamazepine regimens in the long-term treatment of recurrent mood and related psychotic disorders.
    Lenzi A; Lazzerini F; Placidi GF; Cassano GB; Akiskal HS
    Pharmacopsychiatry; 1989 Jan; 22(1):34-7. PubMed ID: 2652160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
    Klassen AF; Miller A; Fine S
    Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with treatment nonadherence among US bipolar disorder patients.
    Baldessarini RJ; Perry R; Pike J
    Hum Psychopharmacol; 2008 Mar; 23(2):95-105. PubMed ID: 18058849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors and course of vocational status, income, and quality of life in people with severe mental illness: a naturalistic study.
    Nordt C; Müller B; Rössler W; Lauber C
    Soc Sci Med; 2007 Oct; 65(7):1420-9. PubMed ID: 17583402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders.
    Serretti A; Malitas PN; Mandelli L; Lorenzi C; Ploia C; Alevizos B; Nikolaou C; Boufidou F; Christodoulou GN; Smeraldi E
    Pharmacogenomics J; 2004; 4(4):267-73. PubMed ID: 15111989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The longitudinal polymorphism of bipolar I disorders and its theoretical implications.
    Marneros A; Roettig S; Roettig D; Tscharntke A; Brieger P
    J Affect Disord; 2008 Apr; 107(1-3):117-26. PubMed ID: 17884177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.